Proteome Sciences (GB:PRM) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Proteome Sciences PLC has reported a surge in customer engagement and service inquiries in 2024, including a significant contract from a US biopharmaceutical company. The firm is optimistic about returning to growth this year, bolstered by the launch of new proteomics services and expansion in the US. Proteome Sciences specializes in proteomics services for drug discovery and biomarker identification, with proprietary technologies like SysQuant® and TMT®MS2.
For further insights into GB:PRM stock, check out TipRanks’ Stock Analysis page.
